March 18, 2005 -- In a session marked by technical considerations, stocks traded lower for most of the day on Friday, though a rally during the final hour took most of the bite out of the slide. The Centient Biotech 200 lost just 3.37 points to 3187.22, a .11% drop, while the NYSE Composite was down .10% and Nasdaq was off by .43%. Alnylam Pharma likes the look of its respiratory syncytial virus in the lab, Cardiome priced a secondary issue of stock without killing its share price, Abgenix has completed patient enrollment in a metastatic colorectal cancer trial, Crucell licensed patents for an Ebola vaccine, Palatin and King Pharma said their drug made Viagra work better, and Valentis climbed suddenly without releasing news. More details...
